Melanoma is a devastating disease. We are investigating new ways to treat and cure this form of cancer. Specifically, we are identifying how the body’s immune system interacts with melanoma and exploring new ways to use one’s own immune cells to destroy the cancer. This is achieved by understanding the interplay between various immune cells during melanoma and current therapies. This knowledge allows us to manipulate the immune cells providing better treatment.
Understanding The Mechanisms Of Action Of The ISCOMATRIX Adjuvant For The Development Of Human Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$401,361.00
Summary
CSL Limited, an Australian owned global biopharmaceutical company, is developing the ISCOMATRIX (IMX) adjuvant for vaccines to prevent and treat serious human disease of global concern (e.g. cancer, pandemic flu, HPV, HCV). This study will identify the mechanisms of action of IMX in generating strong cellular immunity, how to enhance it further by combining with other immuno-modulators so as to develop novel IMX vaccines for the treatment of established cancer and persistent viral infections.
Human Dendritic Cell Subsets And Their Application For Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Immunotherapy is a promising non-toxic strategy for the treatment of many cancers, viruses and other diseases. It works by teaching the patient's own immune system to recognize and destroy the cancer. Specialized blood cells called dendritic cells are essential to this process but they are poorly understood in humans. I aim to investigate the function these cells and use this information to develop new treatments for cancer and viruses.
The Molecular Determinants Of Immunological Tolerance
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
Autoimmune diseases, such as type I diabetes and multiple sclerosis, are debilitating disorders that impose a massive toll on wellbeing in Australia and worldwide. This fellowship will support research aimed at determining the genes and mechanisms that control autoimmunity. New technologies will be brought to bear to track immune cells throughout their development, maturity and malfunction in disease settings. We aim to uncover new therapeutic targets to prevent and reverse autoimmune disease.
This application proposes to study in detail the main target cell for HIV infection, namely CCR5+ CD4 T lymphocytes. After 30 years of the pandemic, fundamental knowledge of these cells, such as locations in the body, differentiation from other lymphocytes, and survival, is still lacking. These attributes determine whether or not they will be infected by HIV, whether this can be prevented by vaccines or CCR5 blocking drugs, and whether their long-term survival results in an inability to eradicat ....This application proposes to study in detail the main target cell for HIV infection, namely CCR5+ CD4 T lymphocytes. After 30 years of the pandemic, fundamental knowledge of these cells, such as locations in the body, differentiation from other lymphocytes, and survival, is still lacking. These attributes determine whether or not they will be infected by HIV, whether this can be prevented by vaccines or CCR5 blocking drugs, and whether their long-term survival results in an inability to eradicate HIV.Read moreRead less
Dendritic Cells In Innate Immunity And Their Potential Clinical Manipulation
Funder
National Health and Medical Research Council
Funding Amount
$443,946.00
Summary
Dendritic cells (DC) are rare cells that are crucial in response to infection and surveillance of damaged tissues. We aim to understand the tools that are expressed by DC that allow them to sense pathogens and the functions of different DC types once a pathogen has been detected. The ultimate aim is to be able to understand and harness the functions of different DC so that we may directly target them upon demand to aid in the course of infection or potentially as tumour therapy.